4D Molecular Therapeutics (FDMT) EBITDA (2020 - 2026)
4D Molecular Therapeutics (FDMT) EBITDA from Mar 31, 2020 to Mar 31, 2026. The TTM 4D Molecular Therapeutics (FDMT) EBITDA is -$175M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
4D Molecular Therapeutics (FDMT) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -12.16% |
| 3 Years TTM | +16.40% |
| 5 Years TTM | +24.57% |
| All Time TTM | +24.57% |
Annual EBITDA change of 4D Molecular Therapeutics (FDMT)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$72M | -53.28% |
| 2025 | -$155M | -15.47% |
| 2024 | -$183M | +68.59% |
| 2023 | -$109M | +0.96% |
| 2022 | -$108M | +54.18% |
| 2021 | -$70M | +26.42% |
| 2020 | -$55M | +10.97% |
| 2019 | -$50M | N/A |
Comparison 4D Molecular Therapeutics (FDMT) five years EBITDA CAGR with competitors
4D Molecular Therapeutics (FDMT) five years EBITDA CAGR is 24.57%.